Welcure Drugs & Pharmaceuticals Limited
Bombay Stock ExchangeTotal Valuation
Welcure Drugs & Pharmaceuticals Limited carries a market capitalization of 29.21M, placing it among publicly traded companies globally. Its enterprise value stands at 223.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29.21M |
| Enterprise Value | 223.80M |
Share Statistics
Welcure Drugs & Pharmaceuticals Limited currently has 1.24B shares outstanding.
| Shares Outstanding | 1.24B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Welcure Drugs & Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 34.78. The price-to-sales ratio is 0.06, and the price-to-book ratio stands at 0.19.
| PE Ratio | 34.78 |
| PS Ratio | 0.06 |
| PB Ratio | 0.19 |
| P/TBV Ratio | 0.24 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
The EV/Sales ratio of 0.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 9.83 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.06 |
| EV / EBITDA | 9.83 |
| EV / EBIT | 9.83 |
| EV / FCF | N/A |
Financial Position
Welcure Drugs & Pharmaceuticals Limited maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.87 |
| Quick Ratio | 0.00 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
Welcure Drugs & Pharmaceuticals Limited posts a return on equity of -14.40 and a return on invested capital of 18.28.
| Return on Equity (ROE) | -14.40 |
| Return on Assets (ROA) | -4.37 |
| Return on Invested Capital (ROIC) | 18.28 |
| Return on Capital Employed (ROCE) | 19.97 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.25 |
Taxes
Over the trailing twelve months, Welcure Drugs & Pharmaceuticals Limited has paid 110.55M in income taxes, reflecting an effective tax rate of 75.50.
| Income Tax | 110.55M |
| Effective Tax Rate | 75.50 |
Stock Price Statistics
Welcure Drugs & Pharmaceuticals Limited's stock has declined approximately -97.79099% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.40.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.79099% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 0.40 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Welcure Drugs & Pharmaceuticals Limited generated 3.66B in revenue and converted that into -169.91M in net income, yielding earnings per share of -0.18. EBITDA reached -73.99M, while operating income came in at -73.99M.
| Revenue | 3.66B |
| Gross Profit | 426.89M |
| Operating Income | -73.99M |
| Pretax Income | -59.35M |
| Net Income | -169.91M |
| EBITDA | -73.99M |
| EBIT | -73.99M |
| Earnings Per Share (EPS) | -0.18 |
Balance Sheet
Total book value stands at 1.24B, with working capital of -556.20M providing operational flexibility.
| Cash & Cash Equivalents | 5.76M |
| Total Debt | N/A |
| Net Debt | -5.76M |
| Equity (Book Value) | 1.24B |
| Book Value Per Share | 1.29 |
| Working Capital | -556.20M |
Margins
Welcure Drugs & Pharmaceuticals Limited operates with a gross margin of 11.68, reflecting its pricing power and cost economics. The operating margin of -2.02 and net profit margin of -4.65 provide insight into operational efficiency.
| Gross Margin | 11.68 |
| Operating Margin | -2.02 |
| Pretax Margin | -1.62 |
| Profit Margin | -4.65 |
| EBITDA Margin | -2.02 |
Scores
Welcure Drugs & Pharmaceuticals Limited posts an Altman Z-Score of 0.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.57 |